Breast cancer has a wide range of causes, symptoms, and predicting factors, which is the most common type of cancer in women. Risk factors associated with genes, lifestyle, hormones and the environment all have an impact on its growth. Although women are the disease's primary sufferers, episodes of male breast cancer make up a small percentage. Diagnostic techniques differ, ranging from imaging and biomarker studies to novel approaches like AI-based detection, all of which improve early detection and ultimately outcome. Despite a delayed decline in mortality rates, issues such as prolonged toxicities, drug resistance and discrepancies in care remain. Latest advancements in nanotechnology, precision pharmaceuticals, and fusion medicines raise the feasibility of safer, more efficient treatment. The continued importance of metastatic disease as a leading cause of death reinforces the need for innovative approaches to organizing long-term care. Emerging scholarship is beginning to clarify the issue of health inequities, including inequities with respect to socioeconomic class, race, geography, and breast cancer outcomes. As we broaden opportunities to identify pathways for earlier detection and personalize treatment pathways through advances in blood-based liquid biopsies and non-invasive monitoring approaches, and more acceptable ways of including patients in clinical trials, patients are also recognizing the growing importance of patient-centred approaches to organizing survivorship care and a socio-psychological framework for care in comprehensive treatment. Future studies on therapeutic combinations of drugs and biomarker-directed therapy will require future advances in health inequities, prevention, diagnosis, and individualization of care in diverse populations.
Bansal et al. (Wed,) studied this question.